Report overview
Monoclonal antibodies are single cell clones of antibodies, a biochemical tool that allows scientists to create antibodies that combine the specificity of specific substances. There are many reasons for the medical community to support the use of monoclonal antibodies in cancer treatment. There are a few clinical trials.
This report contains market size and forecasts of Cancer Monoclonal Antibody Partnering Terms and Agreements in Global, including the following market information:
Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Cancer Monoclonal Antibody Partnering Terms and Agreements market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Asset Purchase Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Cancer Monoclonal Antibody Partnering Terms and Agreements include 3SBio, 4D Pharma, Abbvie, Abzena, Adaptive Biotechnologies, Aeglea BioTherapeutics, Agenus Bio, Ascension and Ascentage Pharma, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Cancer Monoclonal Antibody Partnering Terms and Agreements companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Segment Percentages, by Type, 2021 (%)
Asset Purchase
Collaborative R&D
Joint Venture
Licensing
Other
Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Segment Percentages, by Application, 2021 (%)
Pharmaceutical Industry
Biotechnology
Medical Care
Education and Research
Other
Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Cancer Monoclonal Antibody Partnering Terms and Agreements revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Cancer Monoclonal Antibody Partnering Terms and Agreements revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
3SBio
4D Pharma
Abbvie
Abzena
Adaptive Biotechnologies
Aeglea BioTherapeutics
Agenus Bio
Ascension
Ascentage Pharma
Aslan Pharma
Telix Pharmaceuticals
Basilea Pharmaceutica
Bavarian Nordic
Baxalta
Bayer
Cantargia
Apollomics
Chiome Bioscience
Clovis Oncology
